AR082804A1 - Formas cristalinas de un inhibidor del factor xa - Google Patents
Formas cristalinas de un inhibidor del factor xaInfo
- Publication number
- AR082804A1 AR082804A1 ARP110103159A ARP110103159A AR082804A1 AR 082804 A1 AR082804 A1 AR 082804A1 AR P110103159 A ARP110103159 A AR P110103159A AR P110103159 A ARP110103159 A AR P110103159A AR 082804 A1 AR082804 A1 AR 082804A1
- Authority
- AR
- Argentina
- Prior art keywords
- degrees
- crystalline form
- crystal forms
- factor inhibitor
- betrixaban maleate
- Prior art date
Links
- 239000013078 crystal Substances 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- DTSJEZCXVWQKCL-BTJKTKAUSA-N (z)-but-2-enedioic acid;n-(5-chloropyridin-2-yl)-2-[[4-(n,n-dimethylcarbamimidoyl)benzoyl]amino]-5-methoxybenzamide Chemical class OC(=O)\C=C/C(O)=O.C=1C=C(Cl)C=NC=1NC(=O)C1=CC(OC)=CC=C1NC(=O)C1=CC=C(C(=N)N(C)C)C=C1 DTSJEZCXVWQKCL-BTJKTKAUSA-N 0.000 abstract 3
- 229950011103 betrixaban Drugs 0.000 abstract 2
- 238000000634 powder X-ray diffraction Methods 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37933910P | 2010-09-01 | 2010-09-01 | |
| US201161454396P | 2011-03-18 | 2011-03-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR082804A1 true AR082804A1 (es) | 2013-01-09 |
Family
ID=45773260
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP110103159A AR082804A1 (es) | 2010-09-01 | 2011-08-30 | Formas cristalinas de un inhibidor del factor xa |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US8946269B2 (enExample) |
| EP (1) | EP2611779B1 (enExample) |
| JP (4) | JP2013536864A (enExample) |
| CN (1) | CN103261161B (enExample) |
| AR (1) | AR082804A1 (enExample) |
| AU (1) | AU2011295909B2 (enExample) |
| CA (1) | CA2810004C (enExample) |
| ES (1) | ES2603084T3 (enExample) |
| IL (1) | IL224698A (enExample) |
| NZ (1) | NZ608442A (enExample) |
| PT (1) | PT2611779T (enExample) |
| TW (1) | TW201221128A (enExample) |
| WO (1) | WO2012031017A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8980876B2 (en) | 2010-10-28 | 2015-03-17 | The Procter & Gamble Company | Inhibition of microbial growth by aconitase inhibition |
| WO2013033370A1 (en) | 2011-08-31 | 2013-03-07 | Portola Pharmaceuticals, Inc. | Prevention and treatment of thrombosis in medically ill patients |
| JP6227878B2 (ja) * | 2012-03-16 | 2017-11-08 | ラクステラ・インコーポレイテッドＬｕｘｔｅｒａ，Ｉｎｃ． | 光インターポーザのための方法及びシステム |
| US9200268B2 (en) | 2012-12-27 | 2015-12-01 | Portola Pharmaceuticals, Inc. | Compounds and methods for purification of serine proteases |
| US20140346397A1 (en) | 2012-12-27 | 2014-11-27 | Portola Pharmaceuticals, Inc. | Compounds and methods for purification of serine proteases |
| CN104693114B (zh) * | 2013-12-10 | 2019-08-16 | 四川海思科制药有限公司 | 一种贝曲西班的改进的制备方法 |
| CN105085387A (zh) * | 2014-05-20 | 2015-11-25 | 四川海思科制药有限公司 | 贝曲西班盐及其制备方法和用途 |
| WO2017091757A1 (en) | 2015-11-24 | 2017-06-01 | Portola Pharmaceuticals, Inc. | Isotopically enriched betrixaban |
| CN106995405A (zh) * | 2016-01-25 | 2017-08-01 | 重庆医药工业研究院有限责任公司 | 一种贝曲西班马来酸盐无定型物及其制备方法 |
| US20190300483A1 (en) * | 2016-06-02 | 2019-10-03 | Dr. Reddy's Laboratories Limited | POLYMORPHS OF BETRlXABAN & ITS MALEATE SALT |
| EP3254674A1 (en) | 2016-06-08 | 2017-12-13 | Sandoz Ag | Pharmaceutical compositions of betrixaban maleate |
| EP3293174A1 (en) | 2016-09-09 | 2018-03-14 | Sandoz Ag | Crystalline salts of betrixaban |
| WO2018069936A1 (en) | 2016-10-13 | 2018-04-19 | Mylan Laboratories Limited | Polymorphs and solid dispersion of betrixaban and methods for the preparation thereof |
| CN107382897B (zh) * | 2017-07-10 | 2021-05-04 | 浙江宏元药业股份有限公司 | 一种贝曲西班的中间体及其制备方法和应用 |
| EP3510996A1 (en) * | 2018-01-11 | 2019-07-17 | Sandoz AG | Pharmaceutical compositions of betrixaban |
| CN108570003A (zh) * | 2018-06-01 | 2018-09-25 | 浙江宏元药业股份有限公司 | 一种贝曲西班马来酸盐的一水无定形及其制备方法 |
| CN113905715B (zh) | 2019-06-28 | 2025-04-15 | 宝洁公司 | 光增强处理方法 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9226238D0 (en) | 1992-12-16 | 1993-02-10 | Scherer Ltd R P | Encapsulation apparatus and process |
| US6140351A (en) | 1997-12-19 | 2000-10-31 | Berlex Laboratories, Inc. | Ortho-anthranilamide derivatives as anti-coagulants |
| US6844367B1 (en) | 1999-09-17 | 2005-01-18 | Millennium Pharmaceuticals, Inc. | Benzamides and related inhibitors of factor Xa |
| MXPA02006660A (es) * | 2000-01-07 | 2002-12-13 | Transform Pharmaceuticals Inc | Formacion, identificacion y analisis de diversas formas solidas de alto rendimiento. |
| AU2001245353A1 (en) | 2000-02-29 | 2001-09-12 | Cor Therapeutics, Inc. | Benzamides and related inhibitors of factor xa |
| US6627646B2 (en) | 2001-07-17 | 2003-09-30 | Sepracor Inc. | Norastemizole polymorphs |
| DE10322469A1 (de) | 2003-05-19 | 2004-12-16 | Bayer Healthcare Ag | Heterocyclische Verbindungen |
| US7696352B2 (en) | 2004-06-18 | 2010-04-13 | Millennium Pharmaceuticals, Inc. | Factor Xa inhibitors |
| CN1968922A (zh) | 2004-06-18 | 2007-05-23 | 米伦纽姆医药公司 | 因子xa抑制剂 |
| KR101358574B1 (ko) * | 2005-11-08 | 2014-02-04 | 밀레니엄 파머슈티컬스 인코퍼레이티드 | Ｘａ 인자 억제제, ｎ（5클로로2피리디닐）2［［4［（디메틸아미노）이미노메틸］벤조일］아미노］5메톡시벤자마이드의 약제학적 염 및 다형체 |
| TW200813017A (en) | 2006-05-05 | 2008-03-16 | Millennium Pharm Inc | Factor XA inhibitors |
| US20080051578A1 (en) | 2006-08-24 | 2008-02-28 | Georg Dahmann | Substituted biaryls, process for their manufacture and use thereof as medicaments |
| PT2404906E (pt) | 2006-11-02 | 2015-11-02 | Millennium Pharm Inc | Métodos de sintetizar sais farmacêuticos de um inibidor de fator xa |
| CA2913963A1 (en) | 2006-12-08 | 2008-06-19 | Millenium Pharmaceuticals, Inc. | Unit dose formulations and methods of treating thrombosis with an oral factor xa inhibitor |
| EP2114930A2 (en) | 2007-01-05 | 2009-11-11 | Millennium Pharmaceuticals, Inc. | Factor xa inhibitors |
| AU2008239659B2 (en) | 2007-04-13 | 2013-09-05 | Millennium Pharmaceuticals, Inc. | Combination anticoagulant therapy with a compound that acts as a factor Xa inhibitor |
| EP2586439A1 (en) * | 2007-05-02 | 2013-05-01 | Portola Pharmaceuticals, Inc. | Combination therapy with a compound acting as a platelet ADP receptor inhibitor |
| SI2915564T1 (sl) | 2007-09-28 | 2021-03-31 | Alexion Pharmaceuticals, Inc. | Antidoti za zaviralce dejavnika Ksa in postopki njihove uporabe |
| US8455439B2 (en) * | 2008-11-14 | 2013-06-04 | Portola Pharmaceuticals, Inc. | Antidotes for factor Xa inhibitors and methods of using the same in combination with blood coagulating agents |
| JP5766204B2 (ja) | 2009-12-17 | 2015-08-19 | ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 第Ｘａ因子阻害剤の合成方法 |
| AR082803A1 (es) | 2010-09-01 | 2013-01-09 | Portola Pharm Inc | Metodos y formulaciones para el tratamiento de la trombosis con betrixaban y un inhibidor de la glicoproteina p |
-
2011
- 2011-08-30 AR ARP110103159A patent/AR082804A1/es unknown
- 2011-08-30 TW TW100131157A patent/TW201221128A/zh unknown
- 2011-08-31 PT PT117574673T patent/PT2611779T/pt unknown
- 2011-08-31 ES ES11757467.3T patent/ES2603084T3/es active Active
- 2011-08-31 CA CA2810004A patent/CA2810004C/en not_active Expired - Fee Related
- 2011-08-31 NZ NZ60844211A patent/NZ608442A/en not_active IP Right Cessation
- 2011-08-31 US US13/223,023 patent/US8946269B2/en active Active
- 2011-08-31 AU AU2011295909A patent/AU2011295909B2/en not_active Ceased
- 2011-08-31 CN CN201180052042.4A patent/CN103261161B/zh not_active Expired - Fee Related
- 2011-08-31 JP JP2013527286A patent/JP2013536864A/ja active Pending
- 2011-08-31 WO PCT/US2011/050057 patent/WO2012031017A1/en not_active Ceased
- 2011-08-31 EP EP11757467.3A patent/EP2611779B1/en not_active Not-in-force
-
2013
- 2013-02-13 IL IL224698A patent/IL224698A/en active IP Right Grant
-
2015
- 2015-09-24 JP JP2015187427A patent/JP2015232046A/ja active Pending
-
2017
- 2017-11-16 JP JP2017221050A patent/JP2018024709A/ja active Pending
-
2019
- 2019-04-23 JP JP2019081907A patent/JP2019135258A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2012031017A1 (en) | 2012-03-08 |
| CA2810004C (en) | 2019-09-10 |
| CA2810004A1 (en) | 2012-03-08 |
| AU2011295909B2 (en) | 2015-05-21 |
| PT2611779T (pt) | 2016-11-21 |
| JP2015232046A (ja) | 2015-12-24 |
| ES2603084T3 (es) | 2017-02-23 |
| EP2611779A1 (en) | 2013-07-10 |
| AU2011295909A1 (en) | 2013-04-04 |
| JP2013536864A (ja) | 2013-09-26 |
| NZ608442A (en) | 2015-04-24 |
| CN103261161A (zh) | 2013-08-21 |
| CN103261161B (zh) | 2016-04-27 |
| US8946269B2 (en) | 2015-02-03 |
| JP2018024709A (ja) | 2018-02-15 |
| TW201221128A (en) | 2012-06-01 |
| EP2611779B1 (en) | 2016-08-10 |
| JP2019135258A (ja) | 2019-08-15 |
| IL224698A (en) | 2017-01-31 |
| US20120071519A1 (en) | 2012-03-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR082804A1 (es) | Formas cristalinas de un inhibidor del factor xa | |
| FI3351539T3 (fi) | Kiteinen monohydraattikompleksi 1-syaani-2-(4-syklopropyylibentsyyli)-4-(ß-D-glukopyranos-1-yyli)bentseenistä ja L-proliinista kidevedessä (1:1:1), menetelmät sen valmistamiseksi ja sen käyttö SGLT-estäjänä | |
| AR088755A1 (es) | Formas solidas de un inhibidor de disociacion transtiretina | |
| AR073298A1 (es) | Formas cristalinas del 2-tiazolil-4-quinolil-oxi amidas, composiciones farmaceuticas que las contienen y uso de las mismas en el tratamiento de la infeccion por hcv. | |
| SMT201400126B (it) | Uso di amisulpride per il trattamento di nausea e vomito post-operatori | |
| GT201400033A (es) | Pirimidinas anilladas sustituidas y uso de las mismas | |
| UY40179A (es) | Sal hemi-tolueno de (3s,5s,6r,8s)-8-alil-6-(3-clorofenil)-5-(4- clorofenil)-3-isopropil-8-metil-2,3,5,6,7,8-hexahidrooxazolo [3,2-a]piridin-4-io naftaleno-1-sulfonato, y su preparación | |
| CA2900335C (en) | Synthetic analogs of epipolythiodioxopiperazines and uses thereof | |
| MX342913B (es) | Formas solidas de romidepsina y sus usos. | |
| CR20110457A (es) | Nueva forma cristalina vi de la agomelatina, preparacion y uso de la misma | |
| SMT201400055B (it) | Composti di tioacetato, composizioni e metodi d'uso | |
| AR090151A1 (es) | Compuestos inhibidores de raf | |
| BR112015022782A2 (pt) | composto, composição farmacêutica, combinação, e, uso de um composto | |
| BR112013000650A2 (pt) | poliptídeos de fator ix e métodos de uso dos mesmos. | |
| EP2761583A4 (en) | SECURE E-MAIL CONVERSIONS | |
| IL224450B (en) | Crystalline forms of pyrimido[6,1-a] isoquinolin-4-one compounds | |
| HUE036287T2 (hu) | Vegyület új kalciumsói gyulladásellenes, immunmoduláns és antiproliferatív szerekként | |
| DOP2010000216A (es) | (r)-2-(4-ciclopropansulfonil-fenil)-n-pirazin-2-il-3-(tetrahidropiran-4-il)-propionamida cristalina | |
| DOP2011000329A (es) | Preparacion de solido | |
| PE20130212A1 (es) | Formas polimorficas de st-246 y metodos de preparacion | |
| ES2650604T3 (es) | Nueva forma cristalina VII de agomelatina, método de preparación y utilización de la misma, así como composición farmacéutica que la contiene | |
| PH12015502122A1 (en) | Sovaprevir polymorphs and methods of manufacturing thereof | |
| AR093738A1 (es) | Formas solidas que comprenden inhibidores de ns5a de hcv, sus composiciones y sus usos | |
| CO6400226A2 (es) | Micrólido anti-inflamatorio | |
| HK1217333A1 (zh) | 喹唑啉衍生物的固態形式及其作爲braf抑制劑的用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |